

AD\_\_\_\_\_

AWARD NUMBER: W81XWH-05-1-0359

TITLE: 2006 World Parkinson Congress

PRINCIPAL INVESTIGATOR: Stanley Fahn, M.D.

CONTRACTING ORGANIZATION: World Parkinson Congress, Incorporated  
New York, New York 10032

REPORT DATE: March 2006

TYPE OF REPORT: Final Proceedings

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE (DD-MM-YYYY) 01-03-2006		2. REPORT TYPE Final Proceedings		3. DATES COVERED (From - To) 11 Mar 2005 – 10 Mar 2006	
4. TITLE AND SUBTITLE  2006 World Parkinson Congress				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0359	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Stanley Fahn, M.D.  E-Mail: <a href="mailto:fahn@neuro.columbia.edu">fahn@neuro.columbia.edu</a>				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  World Parkinson Congress, Incorporated New York, New York 10032				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The 2006 World Parkinson Congress (WPC) was held over five days from February 22-26, 2006 in Washington, DC. It was organized to provide an international forum for the latest scientific discoveries, medical practices and caregiver initiatives related to Parkinson's disease (PD). The first-ever WPC attracted more than 3,100 attendees from nearly 60 countries who participated in 150 educational sessions over five days with speakers and audiences representing numerous disciplines. The Congress took place in the Washington Convention Center in Washington, DC. A typical day started with all the attendees meeting to listen to two key note speakers talk about issues pertinent to the daily themes that gave way to a broad range of parallel sessions that took place all day until the closing plenary when everyone came together again to hear from the session chairpersons who summarized their sessions and how the topics related to the daily theme.					
15. SUBJECT TERMS Parkinson's disease, Parkinsonism, congress, conference, international, basic science, clinical science, patients, caregivers, quality of life					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	28	19b. TELEPHONE NUMBER (include area code)

**2006 World Parkinson Congress**  
Final Proceedings for Award Number W81XWH-05-1-0359

**Table of Contents**

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4-25</b>
<b>Key Research Accomplishments.....</b>	<b>26</b>
<b>Reportable Outcomes.....</b>	<b>26</b>
<b>Conclusions.....</b>	<b>26</b>
<b>References.....</b>	<b>27</b>
<b>Supporting Data.....</b>	<b>27</b>
<b>Appendices.....</b>	<b>27</b>
<b>Appendix A - List of Committee members.....</b>	<b>28</b>

## **INTRODUCTION:**

The 2006 World Parkinson Congress (WPC) was a conference organized to provide an international forum for the latest scientific discoveries, medical practices and caregiver initiatives related to Parkinson's disease (PD). Although there have been numerous national and international conferences involving neuroscientists and physicians, until the WPC, there had never been a world-wide gathering of PD groups representing patients, caregivers, health-care providers, voluntary organizations and professionals from academia, government and industry to review and discuss the multifaceted problems of PD and propose solutions. The first-ever WPC attracted more than 3,100 attendees from nearly 60 countries who participated in sessions with speakers and audiences representing numerous disciplines.

## **BODY:**

The information below is the details of the final program that was presented at the WPC. A PDF version of this program included listed as part of the Final Program can be viewed and downloaded from the WPC website at <http://www.worldpdcongress.org/Program/program.cfm>

**Green** highlights indicate SCIENCE sessions

**Yellow** highlights indicate CARE DELIVER/QUALITY OF LIFE sessions

**Blue** highlights indicate POLICY sessions

## **World Parkinson Congress (WPC)**

### **Wed., Feb. 22    Opening Session**

#### **08:00-18:00    Educational Sessions**

#### **Ballroom B**

Educational Sessions were sequentially organized symposia lasting one hour each and covered different aspects of therapeutics.

A full list of the sessions that took place during this part of the program can be viewed on the WPC website at  
[http://www.worldpdcongress.org/Program/industry\\_supported.cfm](http://www.worldpdcongress.org/Program/industry_supported.cfm)

18:30-19:30PM Opening session with welcome talks by:

**I.    Welcome Address: Dr. Stanley Fahn**

**II.   Welcome Address: Michael J. Fox**

**III. Video welcome by Dr. Elias Zerhouni, Director of NIH**

**IV. Speaker: Dr. Oliver Sacks**

**V. Speaker: Mary Baker** (UK) with an introduction to World Declaration on PD

**VI. Dance Performance: Melanie Maar** (Austria) “A Day in the Life of a Parkinson’s Patient”

**VII. Closing Address: Dr. Fahn**

19:30-21:00PM Welcome reception in Exhibit Hall

---

## **Feb 23 Day 1: Theme A: What causes Parkinson’s disease and how does this knowledge influence approaches to care delivery?**

08:15 – 08:30 Meeting Introduction and Welcome (Dr. Fahn)

Overview of meeting

08:30 – 09:30 **Plenary Session** **Hall E**

- **Stanley Fahn** (USA) -- Overview of PD; clinical features and evolution, diagnosis and differential diagnosis, imaging, established and new treatments-30 min.
- **Yoshikuni Mizuno** (Japan) -- Pathology, environmental, epidemiology and genetics-30 min.

10:00 – 21:00 Art Exhibit showcasing work by people living with Parkinson’s

**Room 208B**

10:00 – 11:30 **Parallel Sessions 1-3**

### **“Science 1 “Pathology”**

<b>Schedule Time</b>	<b>Speaker (Oleh Hornykiewicz (Austria) Chair)</b>	<b>Venue</b>
10:00 AM (20 min)	<b>Maria Spillantini</b> (Italy) “The Lewy Body & its protein”	Ballroom A
10:20 AM (20 min)	<b>Etienne Hirsch</b> (France) “Inflammatory Pathology of PD”	Ballroom A
10: 40 AM (20 min)	<b>Jean-Paul Vonsattel</b> (USA) “Staging: Where does it begin?”	Ballroom A
11:00 AM (20 min)	<b>Kurt Jellinger</b> (Austria) “Distinguishing parkinsonian disorders based on their pathology”	Ballroom A

### **“Science 2 “Environmental Factors/Epidemiology”**

<b>Schedule Time</b>	<b>Speaker (Karen Marder (USA) Chair)</b>	<b>Venue</b>
10:00 AM (20 min)	<b>Beate Ritz</b> (USA) "Challenges and Progress in Studying Environmental Causes of Parkinson's Disease"	Ballroom B
10:20 AM (20 min)	<b>Caroline Tanner</b> (USA) "Epidemiology of Parkinson's Disease"	Ballroom B
10: 40 AM (20 min)	<b>Webster Ross</b> (USA) "Preclinical Indicators of Parkinson's Disease in Honolulu-Asia Aging Study"	Ballroom B
11:00 AM (20 min)	<b>Harvey Checkoway</b> (USA) "Gene-Environmental Interactions in Parkinson's Disease"	Ballroom B

<b>“Science 3 “Genetics: Implications for Pathogenesis”</b>		
<b>Schedule Time</b>	<b>Speaker (Peter Heutink (The Netherlands) Chair)</b>	<b>Venue</b>
10:00 AM (20 min)	<b>Valina Dawson</b> (USA) "Unraveling the Pathobiology of DJ-1"	Ballroom C
10:20 AM (20 min)	<b>Vincenzo Bonifati</b> (Italy) "DJ-1-related neurodegeneration: implications for the pathogenesis of Parkinson's disease"	Ballroom C
10:40 AM (20 min)	<b>Enza Maria Valente</b> (Italy) "Clinical and molecular aspects of PINK1-related parkinsonism"	Ballroom C
11:00 AM (20 min)	<b>Thomas Gasser</b> (Germany) "Familial Parkinsonism caused by mutations in LRRK2 (dadarin)"	Ballroom C

<b>“Community 1 “Genetics and Environment”</b>		
<b>Schedule Time</b>	<b>Speaker (Zbigniew Wszolek (USA) Chair)</b>	<b>Venue</b>
10:15 AM (20 min)	<b>Andy Singleton</b> (USA) "Genes, Genetics and PD"	Room 207A/B (820)
10:35 AM (20 min)	<b>J. William Langston</b> (USA) “Environment and PD”	Room 207A/B
10:55 AM (20 min)	<b>Joan Samuelson</b> (USA) “Looking towards the future and the cure of PD”	Room 207A/B

<b>“Community 2 “The Challenges of Delivering Comprehensive Care in PD: U.S. and International Perspectives”</b>		
<b>Schedule Time</b>	<b>Speaker (Peter Hagell (Sweden) Chair)</b>	<b>Venue</b>
10:15 AM (30 min)	<b>Mary Baker</b> (UK) “The Importance of Listening to European Citizens”	Room 206 (400)
10:45 AM (30 min)	<b>Ruth Hagestuen</b> (USA) “Challenges in the U.S.”	Room 206

### **Symposia Session I (12:00-1:25)**

#### **Symposium 1: [Science] Epidemiology, Environmental-Gene Interactions (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speaker (Katrina Gwinn-Hardy (USA) Chair)</b>	<b>Venue</b>
12:00 PM (20 min)	<b>Karen Marder</b> (USA) "The Epidemiology of Dementia in Parkinson's Disease"	201 (400)
12:20 PM (20 min)	<b>Nicholas Wood</b> (UK) “Can genetics help identify environmental risks in PD"	201
12:40 PM (20 min)	<b>Demetrius Maraganore</b> (USA) "High-resolution Whole-genome Association Study of Parkinson's Disease: Susceptibility Gene Discovery, Unencumbered by the Thought Process"	201
1:00 PM (20 min)	<b>Silvia Mandel</b> (Israel) "Gene and protein expression profiling indicates homology between sporadic and familial Parkinson's disease"	

## Symposium 2: [Science] Pathology of Abnormal Proteins in Parkinsonism (12:00 to 1:25)

Scheduled Time	Speakers (Jean-Paul Vonsattel (USA) Chair)	Venue
12:00 PM (25 min)	<b>John Trojanowski</b> (USA) "Parkinson Diseases Linked to Tau Protein Pathologies"	207A/B (820)
12:25 PM (25 min)	<b>Dennis Dickson</b> (USA) "The Neuropathology of Familial Parkinson's Disease: Lessons from LRRK2"	207A/B
12:50 PM (25 min)	<b>Eliezer Masliah</b> (USA) "Interactions of alpha-synuclein with a-beta in the pathogenesis of Parkinson's disease"	207A/B

## Symposium 3: [Science] Development of the Midbrain and Dopamine Neurons (12:00 to 1:25)

Scheduled Time	Speakers (Ronald McKay (USA) Chair)	Venue
12:00 PM (25 min)	<b>Horst Simon</b> (Germany) "The role of the engrailed transcription factor in the survival of mesencephalic dopaminergic neurons"	206 (400)
12:25 PM (25 min)	<b>J. Peter Burbach</b> (The Netherlands) "Genes required for maturation and survival of dopamine neurons of the substantia nigra"	206
12:50 PM (25 min)	<b>Wolfgang Wurst</b> (Germany) Dissection of the Genetic Network Controlling Midbrain Dopaminergic Neuron Development	206

## Symposium 4: "Scientific Research Funding in Neuroscience" (12:00 to 1:25)

Scheduled Time	Speakers (Amy Comstock (USA) Chair)	Venue
12:00 PM (20 min)	<b>Story Landis</b> (US) "NIH Neuroscience Funding"	204A (130)
12:20 PM (20 min)	<b>Remi Quirion</b> (Canada) "CIHR Neuroscience Funding"	204A
12:40 PM (20 min)	<b>Col. Karl Friedl</b> (US—DOD/USAMRAA Neuroscience Funding)	204A

## Symposium 5: [CD/QoL] "Non-drug therapy in early PD: The 'how to' of delivering the diagnosis" (12:00 to 1:25)

Scheduled Time	Speakers (Eric Ahlskog (USA) Chair)	Venue
12:00 PM (35 min)	<b>Jay Nutt</b> (USA) "Setting the Stage"	202A (450)
12:35 PM (35 min)	<b>Julie Carter</b> (USA) "The Importance of 'care' in early stage disease"	202A

### Symposium 6:[CD/QoL]“Reawakenings” (12:00 to 1:25)

Scheduled Time	Speakers (Donald Calne (Canada) Chair)	Venue
12:00 PM (65 min)	<b>Oliver Sacks</b> (USA) “Revisiting ‘Awakenings’ with a documentary and discussion”	202B (420)

### Symposia Sessions II (1:30-2:55)

### Symposium 7: [Science] The Function of New Proteins in Familial PD (1:30 to 2:55)

Scheduled Time	Speakers (Anne Young (USA) Chair)	Venue
1:30 PM (25 min)	<b>Ted Dawson</b> (USA) “The Syns of Parkinson's Disease”	201
1:55 PM (25 min)	<b>Nobutaka Hattori</b> (Japan) "Protein Degradation System in Nigral Degeneration"	201
2:20 PM (25 min)	<b>Robert Nussbaum</b> (USA) “Genetics of non-familial PD”	201

### Symposium 8: [Science] $\alpha$ -Synuclein: Biochemistry, Cell Biology and Function (1:30 to 2:55)

Scheduled Time	Speakers (Peter Lansbury (USA) Chair)	Venue
1:30 PM (25 min)	<b>Michael Schlossmacher</b> (USA) "Monitoring alpha-synuclein steady-state levels in vivo by ELISA"	207A/B (820)
1:55 PM (25 min)	<b>Virginia Lee</b> (USA) "Modulation of Alpha-synuclein Fibril Formation"	207A/B
2:20 PM (25 min)	<b>Leonidas Stefanis</b> (Greece) " $\alpha$ -Synuclein and Protein Degradation"	207A/B

### Symposium 9: [Science] Dopamine: Biosynthesis, Oxidative Metabolism and Neuromelanin (1:30 to 2:55)

Scheduled Time	Speakers (Shu-Leong Ho (Hong Kong) Chair)	Venue
1:30 PM (25 min)	<b>Marc Caron</b> (USA) "Dopamine: Biosynthesis, Oxidative Metabolism and Neuromelanin"	206
1:55 PM (25 min)	<b>Luigi Zecca</b> (Italy) "The Role of Neuromelanin in Aging and Parkinson's Disease"	206
2:20 PM (25 min)	<b>David Sulzer</b> (USA) “The cytosolic dopamine hypothesis of neurodegeneration”	206

### Symposium 10: [CD/QoL] Hope, Healing, and Prevention 1:30 to 2:55

Scheduled Time	Speakers (Judith Blazer (USA) Chair)	Venue
1:30 PM (60 min)	<b>Michael Lerner</b> (USA) “Integrative approaches to living with and preventing Parkinson’s disease”	202A



### Symposium 11: [CD/QoL] World-wide Speech Treatment for PD: LSVT (1:30 to 2:55)

Scheduled Time	Speakers (Cynthia Fox (USA) Chair)	Venue
1:30 PM (25 min)	<b>Lorraine Ramig</b> (USA) "New Advances in speech treatment/LSVT for PD"	202B (420)
1:55 PM (25 min)	<b>Deborah Theodoros</b> (Australia) "Speech Treatment/LSVT: The Australian Experience"	202B
2:20 PM (25 min)	<b>Mara Behlau</b> (Brazil) "Speech Treatment/LSVT: The Brazilian Experience"	202B

### Symposium 12: [CD/QoL] Complementary Medicine I (1:30 to 2:55)

Scheduled Time	Speakers (Allan Kroland (USA) Chair)	Venue
1:30 PM (5 min)	<b>Chair Introduction</b>	204A (130)
1:35 PM (30 min)	<b>Melanie Brandabur</b> (USA) "Integrating Complementary Medicine in the Clinical Treatment of Parkinson's Disease"	204A
2:05 PM (30 min)	<b>Nancy Pearson</b> (USA) "NCCAM Support of Neurodegenerative Disease Research"	204A

### Interactive workshops (3:15 – 4:15)

Time	Topic	Facilitator	Venue
(1)3:15-4:15 PM	[Science] Guam Parkinson-Dementia Complex: An Update	<b>Oliver Sacks</b> (USA)	Room 201
(2)3:15-4:15 PM	[Community] Exercise: Dance for Parkinson's Disease Symptoms and Management: a demonstration class led by Mark Morris Dance Group	<b>Olie Westheimer</b> (USA) & Mark Morris Dance group	Room 203A (70)
(3)3:15-4:15 PM	[Science] Genetic counseling in PD	<b>Tatiana Foroud</b> (USA)	Room 203B (60)
(4)3:15-4:15 PM	[Science] Is biologic surrogacy a reality?	<b>Kenneth Marek</b> (USA)	Room 101 (220)
(5)3:15-4:15 PM	[Science] Opportunities for academe-industry collaboration	<b>Ira Shoulson</b> (USA), <b>Eric Siemers</b> (USA), <b>Cheryl Waters</b> (USA)	Room 102A (140)
(6)3:15-4:15 PM	[Science] The Placebo Effect in Parkinson's Disease: Confounding Factor or Friend?	<b>Jon Stoessl</b> (Canada)	Room 102B (230)
(7)3:15-4:15 PM	[Community] For physical therapists: mobility changes in PD	<b>Meg Morris</b> (Australia)	Room 204A (130)
(8)3:15-4:15 PM	[Community] OT in 2006: A New Approach to an Old Problem	<b>Beth Kirkwood</b> (Australia)	Room 204B (130)
(9)3:15-4:15 PM	[Community] For Social Workers: How to work with PLWP	<b>G. Gonzalez-Ramos</b> (US)& <b>M. Holloway</b> (UK)	Room 204C (160)
(10)3:15-4:15 PM	[Community] Newly diagnosed PD: What should I do?	<b>Mariann Di Minno</b> , RN, (USA)	Room 209A (130)

(11) 3:15-4:15 PM	[Community] For Couples: Living with Parkinson's	<b>Allan and Holly Kroland (USA)</b>	Room 209B (130)
(12) 3:15-4:15 PM	[Science] DEBATE: Levodopa should be used as a first line treatment for newly diagnosed Parkinson's cases	Facilitator: <b>Zvezdan Pirtosek</b> (Slovenia) PRO: <b>William Wiener</b> (USA) vs CON: <b>Oscar Gershanik</b> (Argentina)	Room 209C (120)
(13) 3:15-4:15 PM	[Community] Disclosing the Diagnosis of Parkinson's	<b>Stephen Reich</b> (USA)	Room 208A (70)
(14) 3:15-4:15 PM	[Science] Translational Approach to Neuroprotection: potential for Nicotine in Parkinson's Disease Therapy	<b>Caroline Tanner</b> (USA); <b>Maryka Quik</b> (USA), <b>Bernard Ravina</b> (USA)	

**15:30 – 16:30** Hot topics (Chosen from poster sessions)

**Hall E**

**16:45 – 17:30 Plenary Wrap-Up:** Moderators: Stanley Fahn and Yoshikuni Mizuno—Panelists: Oleh Hornykiewicz, Karen Marder, Peter Heutink, Zbigniew Wszolek, Peter Hagell, Katrina Gwinn-Hardy, Jean-Paul Vonsattel, Anne Young, Amy Comstock, Eric Ahlskog, Donald Calne, Ronald McKay, Peter Lansbury, Shu-Leong Ho, Judith Blazer, Cynthia Fox, Allan Kroland

**Hall E**

**18:00 – 19:00 PM** Presentation: Meet the face of PD through artists' eyes **Room 208B**

## Feb 24 Day 2: Theme B: How do brain cells lose their vitality in Parkinson's disease and how does this knowledge influence approaches to care delivery?

08:30 – 09:30 **Plenary Session I (Science)** (two 30 min talks topics)

**Hall E**

- **David Brooks (UK)** -- Vignette; PD evolution (clinical, neuroimaging, plasticity) - 30 min.
- **Serge Przedborski (USA)** -- What makes the disease progress (inflammation, cell death, excitotoxicity, axonal degeneration, neuroplasticity)-30 min.

10:00 – 21:00 Art Exhibit showcasing work by people living with Parkinson's

**Room 208B**

### **“Science 1 “How Does Knowledge Lead to Neuroprotection?”**

<b>Schedule Time</b>	<b>Speaker</b> (Peter Riederer (Germany), Chair)	<b>Venue</b>
10:00 AM (20 min)	<b>Anthony Schapira</b> (UK) “The scientific basis for Neuroprotection”	Ballroom A
10:20 AM (20 min)	<b>Flint Beal</b> (USA) “Novel Translational Targets for Development of PD Therapeutics”	Ballroom A
10:40 AM (20 min)	<b>Warren Olanow</b> (USA) “Targeting Protein Aggregation”	Ballroom A

11:00 AM (20 min)	<b>Moussa Youdim</b> (Israel) "Polypharmacology or Multifunctional Drugs for Neuroprotection"	Ballroom A
<b>“Science 2 “Non-drug Approaches to Slow Disease”</b>		
<b>Schedule Time</b>	<b>Speaker (Kapil D. Sethi (USA) Chair)</b>	<b>Venue</b>
10:00 AM (20 min)	<b>Michael Zigmond</b> (USA) "Triggering endogenous neuroprotective processes: Studies with cellular and animal models of Parkinson's disease"	Ballroom B
10:20 AM (20 min)	<b>James Joseph</b> (USA) "Fruit and Vegetable Supplementation in Brain Aging: 'Priming' The Brain Against The Ravages of Time"	Ballroom B
10: 40 AM (20 min)	<b>Erwin Montgomery</b> (USA) “Rehabilitation Approaches”	Ballroom B
11:00 AM (20 min)	<b>Meg Morris</b> (Australia) "Attentional strategies and cues: effects on locomotion in PD"	Ballroom B
<b>“Science 3 “Evil Proteins and their Mischief”</b>		
<b>Schedule Time</b>	<b>Speaker (Ted Dawson (USA) Chair)</b>	<b>Venue</b>
10:00 AM (20 min)	<b>Peter Lansbury</b> (USA) "New Therapeutic strategies for Parkinson's disease"	Ballroom C
10:20 AM (20 min)	<b>Mark Cookson</b> (USA) "Synuclein and Dardarin: Protein misfolding and dominant Parkinson's disease"	Ballroom C
10:40 AM (20 min)	<b>Kevin McNaught</b> (USA)“Proteasomal dysfunction in Parkinson's disease”	Ballroom C
11:00 AM (20 min)	<b>Leonard Petrucelli</b> (USA) "Ubiquitin, proteasome or synuclein: Who is the culprit in Parkinson's disease?"	Ballroom C

### **Community 1: “Interdisciplinary Teams Delivering Care: International and U.S. Perspective” (10:15-11:30)**

<b>Scheduled Time</b>	<b>Speakers (Ruth Hagestuen(USA) Chair)</b>	<b>Venue</b>
10:15 AM (30 min)	<b>Nir Giladi, Orna Moore, &amp; Yael Manor</b> (Israel) "The Role of the Interdisciplinary Team and in Increasing the Awareness and Improving the Care of Patients with PD"	207 A/B
10:45 AM (30 min)	<b>Monique Giroux and Sierra Farris</b> (US) “The US perspective”	207 A/B

### **“Community 2 “Understanding and Coping with Depression and Neuropsychological Changes in PD” (10:15-11:30)**

<b>Schedule Time</b>	<b>Speakers (Alessandro Di Rocco(USA), Chair)</b>	<b>Venue</b>
10:15-10:35 (20 min)	<b>Laura Marsh</b> (USA) “Identifying and Treating Depressive Disturbances”	Room 206 (400)
10:35-10:55 (20 min)	<b>Ron Pfeiffer</b> (USA) “Apathy, withdrawal and personality change”	Room 206
10:55-11:15 (20 min)	<b>Joe Friedman</b> (USA) “Drug induced neuropsychiatric symptoms”	Room 206

### **Symposia Session I (12:00 to 1:25)**

### Symposium 1: [Science] $\alpha$ -Synuclein: Animal Models (12:00 to 1:25)

Scheduled Time	Speakers (Eliezer Masliah (USA) Chair)	Venue
12:00 PM (25 min)	<b>Mel Feany</b> (USA) "Genetic Analysis of Alpha-synuclein Toxicity in Drosophila"	201 (400)
12:25 PM (25 min)	<b>Michael Lee</b> (USA) "Alpha-synucleinopathy and synuclein metabolism in transgenic mice" "	201
12:50 PM (25 min)	<b>Kathleen Maguire-Zeiss</b> (USA) Synuclein Overexpression: Presynaptic Dysfunction in a Parkinson's Disease Model	201

### Symposium 2: [Science] Modalities for Following Disease Progression (12:00 to 1:25)

Scheduled Time	Speakers (Wolfgang Oertel (Germany) Chair)	Venue
12:00 PM (25 min)	<b>Werner Poewe</b> (Austria) "The natural history of PD"	202A (450)
12:25 PM (25 min)	<b>Karl Kieburtz</b> (USA) "Clinical Measures of Disease Progression"	202A
12:50 PM (25 min)	<b>Kenneth Marek</b> (USA) "Can We Use Imaging Outcomes to Monitor PD Progression?"	202A

### Symposium 3: [Science] DBS: For Whom and What Approaches (12:00 to 1:25)

Scheduled Time	Speakers (Anna Lena Tornqvist(Sweden) Chair)	Venue
12:00 PM (25 min)	<b>Alim Benabid</b> (France) "Is Deep Brain Stimulation in STN Neuroprotection in Parkinson's Disease?"	202B (420)
12:25 PM (25 min)	<b>Jerrold Vitek</b> (USA) "Controversies in DBS for Parkinson's Disease: Unanswered for PD"	202B
12:50 PM (25 min)	<b>Andres Lozano</b> (Canada) "Advances and Challenges in Surgery for PD"	202B

### Policy Symposium 2: [Policy] "Health Policy Considerations for Chronic Disease in our Aging Societies" (12:00 to 1:25)

Scheduled Time	Speakers (Lisa Shulman (USA), Chair)	Venue
12:00 PM (5 min)	<b>Chair Introduction</b>	204A (130)
12:05 PM (20 min)	<b>Dan Perry</b> (USA) "The Longevity Revolution and the Burden of Chronic Disease"	204A
12:25 PM (20 min)	<b>Susan Dentzer</b> (USA) "Addressing Gaps in Chronic Disease Care in Medicare and Medicaid"	204A
12:45 PM (20 min)	<b>Richard Bringewatt</b> (USA) "Chronic Illness Care in the 21st Century: Targets for Health Systems Transformation"	204A

### **Symposium 5: [CD/QoL] “Family Care: The Role of Optimism?” (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speakers (Julie Carter (USA), Chair)</b>	<b>Venue</b>
12:05 PM (30 min)	<b>Barbara Steward</b> (USA) "Optimism and Pessimism as Early-Warning Sign in Family Care"	204B (130)
12:35 PM (30 min)	<b>Kathryn Zerbe</b> (USA) "Learned Optimism"	204B

### **Symposium 6: [CD/QoL] "The challenges of care delivery: international perspectives" (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speakers (Alessandro Di Rocco (USA) Chair)</b>	<b>Venue</b>
12:05 PM (20 min)	<b>Haruko Tanji</b> (Japan) "Caregiver's burden in Japan"	204C (160)
12:25 (20 min)	<b>Oscar Gershanik</b> (Argentina) "PD care delivery in South America"	204C
12:45(20 min)	<b>Miguel Nicolesis</b> (Brazil) "Building the Future of Brain Research: the International Neuroscience Network Project"	

### **Symposia Session II (1:30-2:55)**

#### **Symposium 7: [Science] Experimental Model Systems (1:30 to 2:55)**

<b>Scheduled Time</b>	<b>Speakers (Serge Przedborski (USA), Chair)</b>	<b>Venue</b>
1:30 PM (25 min)	<b>Jie Shen</b> (USA) "Cellular and Molecular Mechanisms of Familial Parkinsonism Using Genetic Mouse Models"	206 (400)
1:55 PM (25 min)	<b>Tim Greenamyre</b> "Gene-environment interactions in PD: Lessons from the rotenone model"	206
2:20 PM (25 min)	<b>Benjamin Wolozin</b> (USA) "Interaction of Disease Associated Proteins with Mitochondria and the Proteasome in Parkinson's Disease"	206

#### **Symposium 8: [Science] Glia and Neuroinflammation (1:30 to 2:55)**

<b>Scheduled Time</b>	<b>Speakers (Etienne Hirsch (France), Chair)</b>	<b>Venue</b>
1:30 PM (25 min)	<b>Patrick McGeer</b> (Canada) "Factors sustaining inflammation in Parkinson's disease"	207A (450)
1:55 PM (25 min)	<b>J.S. Hong</b> (USA) "Inflammation-mediated Degeneration of Dopaminergic Neurons: Mechanism, Interventions and Relevance to Parkinson's Disease"	207A
2:20 PM (25 min)	<b>Anna Czlonkowska</b> (Poland) "Harmful or protective effect of inflammation in the animal model of Parkinson's Disease?"	207A

### Symposium 9: [Science] Protein Mishandling in PD (1:30 to 2:55)

Scheduled Time	Speakers (David Sulzer (USA), Chair)	Venue
1:30 PM (25 min)	<b>Ana Maria Cuervo</b> (USA) "Chaperone-mediated Autophagy of Modified Synuclein"	207B (420)
1:55 PM (25 min)	<b>Ron Kopito</b> (USA) "Autophagic clearance of aggregated proteins"	207B
2:20 PM (25 min)	<b>Ryosuke Takahashi</b> (Japan) "The role of Pael-R/GPR37 in the life and death of dopaminergic neurons"	207B

### Symposium 10: [CD/QoL] The Role of Nurses in the lives of PLWP(1:30 to 2:55)

Scheduled Time	Speakers (Lisette Bunting-Perry(USA) Chair)	Venue
1:30 PM (25 min)	<b>Susan Heath</b> (USA) "Identification and Management of Non Motor aspects in Parkinson's Disease"	209A(130)
1:55 PM (25 min)	<b>Mariann Di Minno</b> (USA) "The role of the nurse in counseling and support across stages of the disease"	209A
2:20 PM (25 min)	<b>Cathi Thomas</b> (USA) "The Role of the Nurse in Medication Management"	209A

### Symposium 11: [CD/QoL] “Exercise and Parkinson’s Disease” (1:30 to 2:55)

Scheduled Time	Speakers (Becky Farley (USA)- Chair)	Venue
1:30 PM (25 min)	<b>Michael Zigmond</b> (USA) “How exercise affects the brain: Toward a rationale for exercise-induced protection.”	209B
1:55 PM (25 min)	<b>Beth Fisher</b> (USA) "The effect of high-intensity exercise using body-weight supported treadmill training (BWSTT) on neuroplasticity and functional recovery in individuals with Parkinson's disease"	209B
2:20 PM (25 min)	<b>John Argue</b> (USA) "Parkinson's Disease & the Art of Moving"	209B

### Symposium 12: [CD/QoL] “Complementary Medicine II” (1:30 to 2:55)

Scheduled Time	Speaker (Allan Kroland (USA), Chair)	Venue
1:35 PM (25 min)	<b>Bala Manyam</b> (USA) "An Anti-Parkinson Drug with Triple Action"	209C
2:00 PM (25 min)	<b>Karol Traviss</b> (Canada) "Complementary Therapies for PD: A Nutritionist's Perspective"	209C

### Interactive workshops (3:15-4:15)

Scheduled Time	Topic	Facilitator	Venue
(1) 3:15-4:15 PM	[Community] Managing Your Parkinson’s: How to be proactive	<b>David Heydrick</b> (USA)	Room 201
(2) 3:15-4:15 PM	[Community] The role of PLWP and advocacy	<b>Robin Elliott</b>	Room 203A

	organizations in clinical trials	(USA) (Facilitator), <b>Peggy Willocks</b> (USA), <b>Perry Cohen</b> (USA)	
(3) 3:15-4:15 PM	[Community] For Health Professional: Bringing Literacy into Practice	<b>Gale Kittle</b> (USA)	Room 203B
(4) 3:15-4:15 PM	[Community] When children grow up with a chronically parent	<b>David Morley</b> (UK)	Room 204A
(5) 3:15-4:15 PM	[Policy] Domestic & Int'l Policy on Stem Cell Research	<b>Dan Perry</b> (USA) & <b>Bernard Seigel</b> (USA), <b>Amy Comstock</b> (USA)	Room 101
(6) 3:15-4:15 PM	[Community] Functional Changes: What to Expect	<b>Lisa Shulman</b> (USA)	Room 204B
(7) 3:15-4:15 PM	[Community] Empowerment through Education	<b>Joy Leffler</b> (USA)	Room 204A
(8) 3:15-4:15 PM	[Science] The changing of the UPDRS: Old to new	<b>Chris Goetz</b> (USA)	Room 102A
(9) 3:15-4:15 PM	[Science] Enhancing Translational Research	<b>Kevin Biglan</b> (USA)	Room 102B
(10) 3:15-4:15 PM	[Community] "BIG and LOUD" program: A combined approach to PD through speech and physical therapy	<b>Lori Ramig</b> (USA), <b>Becky Farley</b> (USA), <b>Cynthia Fox</b> (USA) & <b>David Mc Farland</b> (USA)	Room 209A (130)
(11) 3:15-4:15 PM	[Community] Therapy in Action	<b>Sheree Loftus</b> (US) and <b>Pnina Isseroff</b> (Israel)	209B (130)
(12) 3:15-4:15 PM	[Community] The Role Optimism Plays in the Life of a Person Living with PD	<b>Tom Isaacs</b> (UK)	209C (120)
(13) 3:15-4:15 PM	[Science] "Movement Normalization Strategies in Parkinson's: Which When and Why?" (Rehabilitative approaches to enabling mobility in people with Parkinson's).	<b>Robert Iansek</b> (Australia) and <b>Beth Kirkwood</b> (Australia)	Room 206 (400)

15:30 – 16:30  
E

Hot topics (Chosen from poster sessions)

**Hall**

16:45 – 17:30 **Plenary Wrap-Up:** Moderators: David Brooks and Serge Przedborski—Panelists: Peter Riederer, Kapil Sethi, Ted Dawson, Ruth Hagestuen, Alessandro Di Rocco, Eliezer Masliah, Wolfgang Oertel, Anna-Lena Tornqvist, Lisa Shulman, Julie Carter, Etienne Hirsch, David Sulzer, Lisette Bunting-Perry, Krissy Hansen, Allan Kroland **Hall E**

---

**Feb 25 Day 3: Theme C: How can Parkinson's disease be identified before clinical onset and how does this knowledge influence experimental approaches to care delivery?**



08:30 – 09:30

**Plenary Session I** (two 30 min talks topics)

**Hall E**

- **J.W. Langston (USA)**-- Familial PD: Autosomal dominant and recessive genes (include synucleinopathies, olfactory; presymptomatic PD personalities-
- **David Eidelberg (USA)** -- Biomarkers and imaging-.

10:00 – 21:00 Art Exhibit showcasing work by people living with Parkinson's **Room 208B**

**“Science 1 “Genetic Testing: Who, When and What to do with the results?”**

Schedule Time	Speaker (Eng King Tan (Singapore), Chair)	Venue
10:00 AM (20 min)	<b>John Hardy (USA)</b> "Is there definitive evidence for environmental modifiers for PD?"	Ballroom A
10:20 AM (20 min)	<b>Peter Heutink (The Netherlands)</b> “Are we sure that all published mutations are pathogenic? Which should be offered for genetic testing?”	Ballroom A
10: 40 AM (20 min)	<b>Kimberley Quaid (USA)</b> "Genetic Testing for Parkinson's Disease: Are we there yet?"	Ballroom A
11:00 AM (20 min)	<b>Michael Conneally (USA)</b> "Testing for Genetic Factors in Parkinson's Disease"	Ballroom A

**“Science 2 “The Role of Neuroimaging and Other Biomarkers”**

Schedule Time	Speaker (Francois Vingerhoets (Switzerland) Chair)	Venue
10:00 AM (20 min)	<b>Matt Stern (USA)</b> “Sense of smell”	Ballroom B
10:20 AM (20 min)	<b>Kirk A. Frey (USA)</b> "VMAT2 and other neurochemical imaging targets as potential PD biomarkers"	Ballroom B
10: 40 AM (20 min)	<b>Joel Perlmutter (USA)</b> "Neuroimaging as Surrogate Endpoints of Parkinson's Disease Studies"	Ballroom B
11:00 AM (20 min)	<b>Hidenao Fukuyama (Japan)</b> "Nicotine receptor of acetylcholine in Parkinson's disease"	Ballroom B

**“Science 3 “Cutting Edge Technologies to Understand PD”**

Schedule Time	Speaker (Ole Isacson (USA) Chair)	Venue
10:00 AM (25 min)	<b>Patrick Aebischer (Switzerland)</b> “Models of Parkinson's disease based on lentiviral-mediated over expression of a-synuclein as a tool for therapeutic approaches”	Ballroom C
10:25 AM (25 min)	<b>Howard Federoff (USA)</b> "Biomolecular profiling to ascertain molecular signatures of disease"	Ballroom C
10:50 AM (25 min)	<b>Jim Eberwine (USA)</b> "RNA Analysis in Individual Neuronal Dendrites: Insights into Parkinson's Disease"	Ballroom C

**“Community 1 “Interdisciplinary Teams Delivering Care in the US & Australia”**

Schedule Time	Speaker (Nir Giladi (Israel) Chair)	Venue
10:15 AM (30 min)	<b>Monique Giroux and Sierra Farris (US)</b> “The US perspective”	Room 207A/B (820)
10:45 AM (30 min)	<b>Robert Iansek &amp; Beth Kirkwood (Australia)</b> "The Role of Interdisciplinary Teams in Management of Parkinson's"	Room 207A/B



## “Community 2 “Music and Parkinson’s Disease”

Schedule Time	Speaker (Connie Tomaino (USA) Chair)	Venue
10:15 AM (30 min)	<b>Connie Tomaino</b> “The Power of Music”	Room 206
10:45 AM (15 min)	<b>Grace Griffith</b> “Music and PD”	Room 206
11:00 AM (15 min)	<b>Heather MacTavish</b> “Drumming and PD	Room 206

## Symposia Session I (12:00 to 1:25)

### Symposium 1: [Science] The Heterogeneity of PD (12:00 to 1:25)

Scheduled Time	Speaker (Kathleen Shannon (USA) Chair)	Venue
12:00 PM (25 min)	<b>Roger Barker</b> (UK) "How many types of Parkinson's disease are there?"	201 (400)
12:25 PM (25 min)	<b>Andrew Lees</b> (UK) “What is Parkinson's disease?"	201
12:50 PM (25 min)	<b>Irene Litvan</b> (USA) "Parkinson disease and dementia: two diseases or a continuum?"	201

### Symposium 2: [Science] Mild Parkinsonism: Is it Recognizable? (12:00 to 1:25)

Scheduled Time	Speaker (Nobuo Yanagisawa (Japan) Chair)	Venue
12:00 PM (25 min)	<b>Eduardo Tolosa</b> (Spain) "Early Non-motor Symptoms in Parkinson's Disease"	202A (450)
12:25 PM (25 min)	<b>Wolfgang Oertel</b> (Germany) "Non motor and motor symptoms in mild parkinsonism – REM-sleep behaviour disorder as a model for early $\alpha$ -synucleinopathy?"	202A
12:50 PM (25 min)	<b>Donald Calne</b> (Canada) "What, exactly, is Parkinson's disease?"	202A

### Symposium 3: [Science] Other Treatable Forms of Parkinsonism (12:00 to 1:25)

Scheduled Time	Speaker (Christopher Goetz (USA) Chair)	Venue
12:00 PM (25 min)	<b>Stewart Factor</b> (USA) “Drug-induced Parkinsonism”	202B (420)
12:25 PM (25 min)	<b>Cindy Comella</b> (USA) "Infectious and post-infectious Parkinsonism"	202B
12:50 PM (25 min)	<b>Carlo Colosimo</b> (Italy) “Vascular Parkinsonism”	202B

### Policy Symposium 3: “Does Health Policy Protect Family Caregivers?” (12:00 to 1:25)

Scheduled Time	Speaker (Lisa Shulman (USA), Chair)	Venue
12:00 PM (25 min)	<b>Carol Levine</b> (USA) “Who Depends on Whom? The Gap between Health Policy and Family Needs”	204A (130)
12:25 PM (25 min)	<b>Jeff Martin</b> (USA) “In Sickness and in Health: Steps to help prevent Parkinson's disease from consuming a marriage and a family”	204A
12:50 PM (25 min)	<b>Suzanne Mintz</b> (USA) "Empowering Family Caregivers to Be a Force for Health Policy Change"	204A

**Symposium 5: [CD/QoL] “Living Transitions: Helping Families with Difficult Decisions”(12 to 1:25)**

<b>Scheduled Time</b>	<b>Speakers (Patricia Archbold(USA), Chair)</b>	<b>Venue</b>
12:00 PM (25 min)	<b>Heather Young</b> (USA) "Living Environments: Helping Families Through the Process of Change"	204B (130)
12:25 PM (25 min)	<b>Carol Whitlatch</b> (USA) "Family Dynamics in Decision Making"	204B
12:50 PM (25 min)	<b>Lynn Feinberg</b> (USA) “The State of the States in Family Caregiver Support: Implications for Policy and Practice”	204B

**Symposium 6: [CD/QoL] “Intimacy and Sexuality in PD” (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speakers (Orna Moore (Israel), Chair)</b>	<b>Venue</b>
12:00 PM (30 min)	<b>Gila Bronner</b> (Israel) Sexual Dysfunction in Parkinson's Disease- Dynamic and Unpredictable	204C (160)
12:30 PM (30 min)	<b>Susan Calne</b> (Canada) “Changes in Sexual Intimacy”	204C

**Symposia Session II (1:30 – 2:55)****Symposium 7: [Science] Clinical Trials: Educating Participants (1:30 to 2:55)**

<b>Scheduled Time</b>	<b>Speakers (Chair) Alberto Avasconcellos (Portugal)</b>	<b>Venue</b>
1:30 PM (25 min)	<b>Robin Elliott</b> (USA) "Increasing Public Awareness of Clinical Trials in Parkinson's Disease: the North American Experience"	206 (400)
1:55 PM (25 min)	<b>Cristina Sampaio</b> (Portugal) "Increasing Public Awareness of Clinical Trials in Parkinson's Disease: the European Experience"	206
2:20 PM (25 min)	<b>Ira Shoulson</b> (USA) "Communicating Evidence for Research Participant Decision Making in Parkinson's Disease Clinical Trials"	206

**Symposium 8: [Science] Adenosine A2A Antagonists (1:30 to 2:55)**

<b>Scheduled Time</b>	<b>Speakers (Peter Jenner(UK) Chair)</b>	<b>Venue</b>
1:30 PM (25 min)	<b>Michael Schwarzschild</b> (USA) "Neuroprotective and Anti-dyskinetic Potential of Adenosine A2A Blockers"	207A
1:55 PM (25 min)	<b>Michael Morelli</b> (Italy) “Modulatory role of adenosine A2A receptors in basal ganglia as basis for the use of A2A antagonists in the treatment of Parkinson's disease”	207A
2:20 PM (25 min)	<b>Kjell Fuxe</b> (Sweden) "Experimental studies and theoretical aspects on A2A/D2 receptor interactions in model of Parkinson's disease: Relevance for l-dopa induced dyskinesias"	207A

### Symposium 9: [Science] Medium Spiny Neuron Plasticity in PD (1:30 to 2:55)

Scheduled Time	Speakers (David Standaert (USA) Chair)	Venue
1:30 PM (25 min)	<b>Ariel Deutch</b> (USA) "Structural Changes in the Striatum in Parkinson's Disease"	207B
1:55 PM (25 min)	<b>D. James Surmeier</b> (USA) "Dopamine, calcium channels, dendrites and striatal plasticity in Parkinson's disease"	207B
2:20 PM (25 min)	<b>Paolo Calabresi</b> (Italy) "Synaptic and molecular mechanisms underlying pathological synaptic plasticity in experimental Parkinson's disease"	207B

### Symposium 10: [CD/QoL] "Racial and Ethnic Differences in Family Caregiving" (1:30 to 2:55)

Scheduled Time	Speaker (Gladys Gonzalez-Ramos (USA), Chair)	Venue
1:30 PM (25 min)	<b>Donna Benton</b> "African American Caregivers: Strength and Hope"	209A (130)
1:55 PM (25 min)	<b>Alba Bonetti</b> (Italy) "The Italian Experience of Caregiving"	209A
2:20 PM (25 min)	<b>Sandra Picot</b> (USA) "Does Ethnicity Influence the Stress and Coping Process of Parkinson Dyads?"	209A

### Symposium 11: [CD/QoL] "Patient-Reported Outcome Measurement" (1:30 to 2:55)

Scheduled Time	Speaker (Gun-Marie Hariz (Sweden) Chair)	Venue
1:30 PM (35 min)	<b>Peter Hagell</b> (Sweden) Health Status Measurement	209B (130)
2:05 PM (35 min)	<b>Mickie Welsh</b> (USA) "QoL measurements"	209B

### Symposium 12:[CD/QoL]"Cognitive Changes" (1:30 to 2:55)

Scheduled Time	Speakers (Murat Emre (Turkey) Chair)	Venue
1:30 PM (25 min)	<b>Erik Wolters</b> (The Netherlands) "Early Cognitive Dysfunction in Parkinson's Disease"	204C (160)
1:55 PM (25 min)	<b>Amos Korczyn</b> (Israel) "Cognitive decline and dementia in advanced PD"	204C
2:20 PM (25 min)	<b>S.J. Baloyannis</b> (Greece) "Ethical and philosophical consideration on the emotional changes in PD"	204C

### Interactive workshops

Scheduled Time	Topic	Facilitator	Venue
(1) 3:15-4:15 PM	[Community] Art as Therapy	<b>Nancy Tingey</b> (UK)	Room 208A
(2) 3:15-4:15 PM	[Science] Balance performance, falls and fear of falling in severe PD	<b>Mia Nilsson</b> (Sweden)	Room 203A
(3) 3:15-4:15 PM	[Community] Activity limitations/ADL assessments	<b>Gun-Marie Hariz</b> (Sweden)	Room 203B
(4) 3:15-4:15 PM	[Community] For Caregivers: changes in intimacy and	<b>Susan Calne</b>	Room 304

	sexuality	(Canada)	
(5) 3:15-4:15 PM	[Community] Forum for PWP: understanding changes in intimacy and sexuality	<b>Gila Bronner</b> (Israel)	Room 305
(6) 3:15-4:15 PM	[Community] Family care in rural environments: Special Needs and Challenges of Rural Caregivers	<b>Kathleen Buckwalter</b> (USA)	Room 306
(7) 3:15-4:15 PM	[Community] The Case for a Specialized Electronic Health Record for Parkinson's Care: Differing Patient, Physician and Health System Perspectives	<b>Bill Tenhoor</b> (USA)	Room 204A
(8) 3:15-4:15 PM	[Science] Post-Neurosurgery Speech Changes & Treatment	<b>Deborah Theodoros</b> (Australia)	Room 204B
(9) 3:15-4:15 PM	[Science] Sleep disturbances in Parkinson's disease	<b>Cynthia Comella</b> (USA)	Room 204C
(10) 3:15-4:15 PM	[Community] PLWP and caregivers: finding trustworthy info on the Internet	<b>CANCELLED</b>	Room 209A
(11) 3:15-4:15 PM	[Science] For Professional: Effects of behavioral changes on motor symptoms and functional ability in Parkinson's disease	<b>Karen Anderson</b> (USA)	Room 209B
(12) 3:15-4:15 PM	[Community] Brain Health & Wellness	<b>Paul Nussbaum</b> (USA)	Room 209C
(13) 3:15-4:15	[Community] The mid-level practitioner on the interdisciplinary team	<b>Monique Giroux</b> (USA) & <b>Sierra Farris</b> (USA)	Room 205 (40)

15:30 – 16:30 Hot topics (Chosen from poster sessions)

**Hall**

**E**

16:45 – 17:30 **Plenary Wrap-Up**

**Moderators:** J.W. Langston and David Eidelberg

**Panelists:** Eng King Tan, Francois Vingerhoets, Ole Isacson, Nir Giladi, Marti Haykin, Kathleen Shannon, Nobuo Yanagisawa, Christopher Goetz, Lisa Shulman, Patricia Archbold, Orna Moore, Peter Jenner, David Standaert, Gladys Gonzalez-Ramos, Gun-Marie Hariz, Murat Emre **Hall E**

---

## Feb 26 Day 4: Theme D: How can the needs of Parkinson's disease patients and families be met in relieving symptoms, improving quality-of-life and slowing progression of illness?

08:30 – 09:30

**Plenary Session** (two 30 min talks)

**Hall E**

- **Anthony Lang** (Canada), Non-dopaminergic motor and non-motor features of PD: Recognition and treatment (Freezing, affective components, dementia, sleep disorders- 30 min.
- **Murat Emre** (Turkey) Brain mechanisms underlying cognitive alteration, depression, and sleep disorders- 30 min.

**“Science 1 “Symptomatic Therapy for the Motor Component”**

Schedule Time	Speaker (Guenther Deuschl (Germany) Chair)	Venue
10:00 AM (20 min)	<b>Joseph Jankovic</b> (USA) “Clinical Features and Classification of Motor Symptoms of PD and Levodopa-related Motor Complications” ( <i>along with videos</i> )	Ballroom A
10:20 AM (20 min)	<b>Jay Nutt</b> (USA) "Causes and management of levodopa-induced dyskinesia (hyperkinetic)"	Ballroom A
10:40 AM (20 min)	<b>Eldad Melamed</b> (Israel) "Causes and Management of Levodopa-Associated Motor Fluctuations in Parkinson's Disease (hypokinetic)"	Ballroom A
11:00 AM (20 min)	<b>Olivier Rascol</b> (France) "Future symptomatic therapies for Parkinson's disease (concepts and development status)"	Ballroom A

**“Science 2 “Symptomatic Therapy for Non-motor Components: Sleep Disturbances, Depression, Dementia”**

Schedule Time	Speaker (Roger Kurlan (USA) Chair)	Venue
10:00 AM (25 min)	<b>Yves Agid</b> (France) "Psychic Disorders in Parkinson's Disease: Anatomic-Functional Bases and Treatment"	Ballroom B
10:25 AM (25 min)	<b>Vladimir Kostic</b> (Yugoslavia) "Diagnosis and treatment of depression in Parkinson's disease"	Ballroom B
10:50 AM (25 min)	<b>Justo Garcia de Yebenes</b> (Spain) "Phenotypes and pathogenesis of dementia in PD"	Ballroom B

**“Science 3 “Novel Therapies”**

Schedule Time	Speaker (Howard Federoff (USA) Chair)	Venue
10:00 AM (25 min)	<b>Howard Gendelman</b> (USA) “Immunoregulatory Therapy for Parkinson's Disease	Ballroom C
10:25 AM (25 min)	<b>Ronald McKay</b> (USA) "Will Stem Cell Biology Contribute to our Understanding of Parkinson's Disease?"	Ballroom C
10:50 AM (25 min)	<b>Patrik Brundin</b> (Sweden) “Restorative Therapies in Parkinson's Disease”	Ballroom C

**“Community 1 “How to develop interdisciplinary health professional teams for PD”**

Schedule Time	Speaker (Robert Iannsek (Australia) Chair)	Venue
10:15 AM (5 min)	<b>Chair Introduction</b>	Room 207A/B (820)
10:20 AM (30 min)	<b>Monique Giroux</b> (USA) “Starting interdisciplinary teams”	Room 207A/B
10:50 AM (30 min)	<b>Teresa Drinka &amp; Phillip Clark</b> (USA) “Overlooked Essentials of Interdisciplinary Teamwork: Organization, Education, and Maintenance”	Room 207A/B

**“Community 2 “Pain, Palliative Care and PD”**

Schedule Time	Speaker (Barbara Habermann, Chair)	Venue
10:15 AM (5 min)	<b>Chair Introduction</b>	Room 206 (400)
10:15 AM (30 min)	<b>Susan Heath</b> (USA) “Pain and other Non-Motor Symptoms in Parkinson's”	Room 206

10:45AM (30 min)	<b>Lisette Bunting-Perry (USA)</b> "Palliative Care in Parkinson's Disease"	Room 206
------------------	---	----------

## **Symposia Sessions I**

### **Symposium 1: [Science] The Future of Gene Therapy (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speaker (Martha Bohn (USA) Chair)</b>	<b>Venue</b>
12:00 PM (25 min)	<b>Jeffrey Kordower (USA)</b> "Cell and gene therapy for Parkinson's disease"	201 (400)
12:25 PM (25 min)	<b>Anders Björklund (Sweden)</b> "The Neuroprotective Therapy Using GDNF Gene Transfer"	201
12:50 PM (25 min)	<b>Krystof Bankiewicz (USA)</b> "Viral Vector Delivery of Therapeutic Factors in the Brain"	201

### **Symposium 2: [Science] "The Future of Stem Cell Therapy" (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speaker (Lorenz Studer (USA), Chair)</b>	<b>Venue</b>
12:00 PM (25 min)	<b>Steven Goldman (USA)</b> "The Selective Generation, Use and Pitfalls of Human Dopaminergic Progenitors"	202A (450)
12:25 PM (25 min)	<b>Clive Svendsen (USA)</b> "Combining Stem Cell and Growth Factor Therapy for Parkinson's Disease"	202A
12:50 PM (25 min)	<b>Evan Snyder (USA)</b> "The Developmental Role of Stem Cells may Suggest Novel Therapeutic Applications"	202A

### **Symposium 3: [Science] "Basal Ganglia Physiology and Pathophysiology" (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speaker (Chris Fibiger (USA), Chair)</b>	<b>Venue</b>
12:00 PM (25 min)	<b>Ann Graybiel (USA)</b> "Ensemble recording in macaque cortico-basal ganglia loops"	202B (420)
12:25 PM (25 min)	<b>Mahlon DeLong (USA)</b> "Parkinson's Disease: a Circuit Disorder"	202B
12:50 PM (25 min)	<b>Jonathan Mink (USA)</b> "Basal Ganglia Function With and Without Dopamine: The Importance of Focus"	202B

### **Policy Symposium 4: "Advocacy Symposium: How to Effect Change" (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speaker (Peggy Willocks (USA), Chair)</b>	<b>Venue</b>
12:00 PM (25 min)	<b>Amy Comstock (USA)</b> "Giving Voice to Parkinson's: Effecting Change Through Public Policy"	204A (130)
	<b>Morton Kondracke (USA)</b> "How Telling "Your" Story Makes a Difference"	

**Symposium 5: [CD/QoL] “Working in the Community: Outreach and Pathways to PWP” (12 to 1:25)**

<b>Scheduled Time</b>	<b>Speaker (Gladys Gonzalez-Ramos (USA) Chair)</b>	<b>Venue</b>
12:00 PM (30 min)	<b>Margaret Holloway</b> (UK) "Pathways through care: a patient/carer-led approach to the management of Parkinson's disease in the community"	204B (130)
12:25 PM (30 min)	<b>Ken Bergmann</b> (USA) "African Americans and Parkinson's Disease in South Carolina"	204B

**Symposium 6: [CD/QoL] “Long-term family care giving: Implications for Health” (12:00 to 1:25)**

<b>Scheduled Time</b>	<b>Speaker (Ellen Abramson (USA), Chair)</b>	<b>Venue</b>
12:00 PM (35 min)	<b>Barbara Stewart</b> (USA) “Care Giving: Implications for Health	204C (160)
12:35 PM (35 min)	<b>Dag Aarsland</b> (Norway) “Which Clinical Features are Associated with Caregiver Distress?”	204C

**Symposia Session II (1:30-2:55)****Symposium 7: [Science] Co-morbidities in PD (1:30 to 2:55)**

<b>Scheduled Time</b>	<b>Speaker (Irene Richard (USA) Chair)</b>	<b>Venue</b>
1:30 PM (25 min)	<b>Guenther Deuschl</b> (Germany) "Common and uncommon tremors in typical and atypical PD"	206 (400)
1:55 PM (25 min)	<b>William Weiner</b> (USA) "The prevalence of other medical conditions in patients with Parkinson`s disease"	206
2:20 PM (25 min)	<b>Mark Stacy</b> (USA) “Repetitive Behaviors”	206

**Symposium 8: [Science] Pathways to Cell Death in Dopamine Neurons (1:30 to 2:55)**

<b>Scheduled Time</b>	<b>Speaker (Anders Björklund (Sweden) Chair)</b>	<b>Venue</b>
1:30 PM (25 min)	<b>Robert Burke</b> (USA) "Kinase Signaling Pathways: Potential Therapeutic Targets in Parkinson's Disease"	207A (450)
1:55 PM (25 min)	<b>Miquel Vila</b> (USA) "Targeting programmed Cell Death in Experimental Parkinsonism"	207A
2:20 PM (25 min)	<b>Martha Bohn</b> (USA) "Gene Therapy Approaches to Protect DA Neurons Against Cell Death"	207A

### Symposium 9: [Science] Side Effects of Symptomatic Therapy (1:30 to 2:55)

Scheduled Time	Speaker (Joseph Jankovic(USA) Chair)	Venue
1:30 PM (20 min)	<b>Erwan Bezard</b> (France) "Levodopa-induced dyskinesia: from single cell to network (re)organizations in animal models"	207B (420)
1:50 PM (20 min)	<b>Jose Obeso</b> (Spain) "Pathophysiology of levodopa-induced dyskinesias in PD: Relevance for newer therapeutic developments"	207B
2:10 PM (20 min)	<b>Mitsutoshi Yamamoto</b> (Japan) "Psychiatric problems in the treatment of PD"	207B
2:30 PM (20 min)	<b>Fabrizio Stocchi</b> (Italy) "Systemic Side Effects of Symptomatic Therapy"	

### Symposium 10: [CD/QoL] "Interventions for Family Caregiving in Later Stage Disease" (1:30 to 2:55)

Scheduled Time	Speaker (Jennie Posen (Israel) Chair)	Venue
1:30 PM (25 min)	<b>Patricia Archbold</b> (USA) "Interventions to Strengthen Family Care"	206 (400)
1:55 PM (25 min)	<b>Richard Schulz</b> (USA) "Health Effects of Caregiving: Transitions and Treatments"	206
2:20 PM (25 min)	<b>Orna Moore</b> (Israel) "Clinic for Family Caregivers of PD Patients"	206

### Symposium 11: [CD/QoL] "The Role of Patients in Development of New Therapies" (1:30 to 2:55)

Scheduled Time	Speaker (Ira Shoulson (USA) Chair)	Venue
1:35 PM (15 min)	<b>Perry Cohen</b> (USA)	207A (450)
1:45 PM (25 min)	<b>Russell Katz</b> (USA)	207A
2:10 PM (25 min)	<b>Craig Smith</b> (USA)	207A

### Symposium 12: [CD/QoL] "Parkinson's Disease in the Developing World" (1:30 to 2:55)

Scheduled Time	Speaker (Aleksandar Janca, Chair & Speaker)	Venue
1:30 PM (20 min)	<b>Aleksandar Janca</b> (Australia) "WHO Commitment to PD"	207B (420)
1:55 PM (15 min)	<b>Mary Baker</b> (UK) "Update on WHO Working Group on Parkinson's"	207B
2:20 PM (15 min)	<b>Alessandro Di Rocco</b> (USA) "WFN Initiative for PD in the Developing World"	207B
2:05 PM (15 min)	<b>Jonathan Carr</b> (South Africa) "Parkinson's Disease in the Developing World"	207B

### Interactive workshops (3:15-4:15)

Scheduled Time	Topic	Facilitator	Venue
(1) 3:15-4:15 PM	[Community] The challenge of living creatively with Parkinson's	<b>Ruth Hagestuen</b> (USA) & <b>Lucy Roucis</b> (USA)	Room 208A
(2) 3:15-4:15 PM	[Policy] Public Health Policy and PD	<b>CANCELLED</b>	Room 203A



(3) 3:15-4:15 PM	[Community] From Home to Hospital: Intergrated Care Chain For Parkinson's Disease	<b>Bastiaan Bloem</b> (The Netherlands)	Room 203B
(4) 3:15-4:15 PM	[Community] For Caregivers: End of Life Issues <b>AND</b> What is hospice? When to use it?	<b>Avinoam Reches</b> (Israel) & <b>Marge Thurin</b> (USA)	Room 304
(5) 3:15-4:15 PM	[Community] Choosing a Care Facility	<b>Heather Young</b> (USA)	Room 305
(6) 3:15-4:15 PM	[Community] Exercise: Motivating moves, tai chi and PD	<b>Janet Hamburg</b> (USA) & <b>Sheree Loftus</b> (USA)	Room 306
(7) 3:15-4:15 PM	[Community] Therapeutic Value of Creativity in PD	<b>Adam Koss</b> (USA), <b>Steve Frucht, MD</b> (USA), <b>Rose Wichman</b> (USA), <b>Marjorie Johnson</b> (USA)	Room 204A
(8) 3:15-4:15 PM	[Policy] Elder Law: What every PWP, their caregivers and doctors should know about their legal rights	<b>CANCELLED</b>	Room 204C
(9) 3:15-4:15 PM	[Community] Complementary Medicine	<b>Jill Marjama-Lyons</b> (USA)	Room 209A
(10) 3:15-4:15 PM	[Science & Community] Speech and Swallowing in Advanced PD	<b>Deborah Theodoros</b> (Aust.), <b>Lori Ramig</b> (US), <b>Ron Cole</b> (US) & <b>Yael Manor</b> (Israel)	Room 209B
(11) 3:15-4:15 PM	[Community] For Caregivers: "Taking care of yourself"	<b>Barbara Habermann</b> (USA)	Room 209C
(12) 3:15-4:15 PM	[Community] Role of Nurses in Managing PD	<b>Lisette Bunting-Perry</b> (USA) & <b>Gwen Vernon</b> (USA)	Room 206
(13) 3:15-4:15	[Community] For PWP & caregivers: depression and anxiety	<b>Laura Marsh</b> (USA)	Room 205 (40)

**15:30 – 16:30**

**Hot topics** (Chosen from poster sessions)

**Hall E**

**16:45 – 17:30**

**Closing Plenary:** Moderators: Anthony Lang and Murat Emre-- Panelists Guenther Deuschl, Roger Kurlan, Howard Federoff, Robert Iansek, Barbara Habermann, Martha Bohn, Lorenz Studer, Chris Fibiger, Peggy Willocks, Gladys Gonzalez-Ramos, Irene Richard, Anders Björklund, Joseph Jankovic, Jennie Posen, Ira Shoulson, Aleksandar Janca

**Hall E**

**17:30-18:00**

**Closing Remarks** (Stanley Fahn)

---

## KEY RESEARCH ACCOMPLISHMENTS:

- Held first-ever Congress on Parkinson's that included the whole community (clinicians, researchers, allied health professionals, patients and caregivers).
- Drew an attendance of more than 3,100 people from nearly 60 countries, considered highly successful for first-ever Congress.
- Built network of more than 100 organizational partners, many of which it was their first time collaborating with other PD groups. This coalition is already discussing the 2009 WPC and taking steps to improve the access and awareness among the community.
- Helped to usher in a new format for meetings on PD that will continue to meld outstanding scientific and educational programs for everyone touched by PD.

## REPORTABLE OUTCOMES:

*"Abstracts of the First World Parkinson Congress,"* Movement Disorders Official Journal of the Movement Disorder Society, Volume 21/Supplement 13, 2006, p1-165. [Hard copy available upon request.]

*"Creativity & Parkinson's Journal,"*. A publication of the artwork selected and displayed in the Creativity & Parkinson's Exhibit during the World Parkinson Congress. [Hard copy available upon request.]

The WPC achieved a total estimated audience of more than 420 million. Twenty-three print articles in newspapers and magazines were reported with a combined circulation of all print publications reaching nearly 11 million. A total of 78 radio and television stations broadcast the story in 49 markets, reaching an estimated audience of 22 million. In addition, 246 web sites posted articles about the WPC. [Hard copy of full press list upon request].

World Parkinson Congress website: [www.worldpdcongress.org](http://www.worldpdcongress.org)

## CONCLUSION:

The World Parkinson Congress was successful as judged by attendees' comments collected during the WPC and in an online survey posted on the WPC website (comments are still being collected). The attendance numbers exceeded the expectations of the WPC leadership with a total of 3,161 attendees. For a one disease meeting, focusing on just Parkinson's, the turnout and press response were outstanding. The broad selection of educational sessions and list of renowned speakers drew medical professionals and people with Parkinson's from nearly 60 countries. Comments were made to the WPC staff from one clinician who said he was excited that he was able to hear and meet in person some of the scientists whose work he had been reading about for years but who he had never had the opportunity to meet. The cross-fertilization of professionals in the field was the first step to bringing the community closer and to building more collaborative research projects in an effort to find a cure for this devastating disease. [Hard copy of final survey feedback will be available upon request in mid-June].

## REFERENCES:

*“Abstracts of the First World Parkinson Congress,”* Movement Disorders Official Journal of the Movement Disorder Society, Volume 21/Supplement 13, 2006, p1-165. [Hard copy available upon request.]

Website: [www.worldpdcongress.org](http://www.worldpdcongress.org)

## SUPPORTING DATA:

Attendance breakdown from the WPC. Please note that the number of ‘Exhibitors’ and ‘Guests’ also includes health professionals and people with Parkinson’s.

	Totals
Exhibitors (approx. %40 health professionals or PwPs)	276
Press	41
People with Parkinson's/caregivers	773
Guests (approx %50 with PD)	292
Health Professionals (MD, DO, RN, PT, OT, PhD, SLP, DSW etc)	1779
	3161

## APPENDICES:

Appendix A: WPC Committee members

---

## Appendix A

### WPC Committee Members

#### **Steering Committee**

Stanley Fahn, M.D. (Chair)  
 Mary Baker, MBE  
 Judith Blazer, M.S.  
 Donald Calne, M.D.  
 Kitty Clarence-Smith, M.D.  
 Amy Comstock, Esq.  
 Ariel Y. Deutch, M.D.  
 Robin Elliott  
 Marian Emr  
 Howard Federoff, M.D., Ph.D.  
 Ruth Hagestuen, RN  
 Franz Hefti, Ph.D.  
 J. William Langston, M.D.  
 Andrew Lees, M.D.  
 Yoshikuni Mizuno, M.D.  
 Diane Murphy, Ph.D.  
 C. Warren Olanow, M.D.  
 Gianni Pezzoli, M.D.  
 Ira Shoulson, M.D.  
 G. Frederick Wooten, M.D.

#### **Communication Committee**

Marian Emr (Chair)  
 Robin Elliott  
 Christiana Evers, MPA  
 Michelle Schwartz

#### **Finance Committee**

C. Warren Olanow, M.D.  
 (Chair)  
 Robert Burke, M.D.  
 Werner Poewe, M.D.  
 Matthew Stern, M.D.

#### **Audit Committee**

Amy Comstock, Esq. (Chair)  
 Patric Donaghue  
 Jose Garcia-Pedrosa, Esq.

#### **Organization and Government Relations Committee**

Judith Blazer, M.S. (Chair)  
 Amy Comstock, Esq.  
 Robin Elliott

#### **Program Committee**

##### *Scientific and Research Committee*

Howard Federoff, M.D., Ph.D.  
 (Chair)  
 M. Flint Beal, M.D.  
 Nancy Bonini, Ph.D.  
 Robert E. Burke, M.D.  
 Ted M. Dawson, M.D., Ph.D.  
 Ariel Y. Deutch, Ph.D.  
 Col. Karl Friedl, Ph.D.  
 Ruth Hagestuen, R.N.  
 Peter Heutink, M.D.  
 Etienne Hirsch, Ph.D.  
 Russell Katz, M.D.  
 Annette Kirshner, Ph.D.  
 Cindy Lawler, Ph.D.  
 Col. Brian Lukey, Ph.D.  
 Ronald McKay, M.D.  
 Yoshikuni Mizuno, M.D.  
 Diane Murphy, Ph.D.  
 C. Warren Olanow, M.D.  
 Tony Phelps, Ph.D.  
 Serge Przedborski, M.D.,  
 Ph.D.  
 Ira Shoulson, M.D.

##### *Care Delivery and Quality of Life Subcommittee*

Ruth Hagestuen, R.N. (Chair)  
 Mary Baker, MBE  
 Judith Blazer, M.S.  
 Alba Bonetti, R.N.  
 Julie Carter, R.N.  
 Alessandro DiRocco, M.D.  
 Howard Federoff, M.D., Ph.D.  
 Leslie Findlay, Ph.D.  
 Oscar Gershanik, M.D.  
 Nir Giladi, M.D.

Gladys González-Ramos,  
 Ph.D.

Peter Hagell, R.N., Ph.D.  
 Robert Ianseck, Ph.D., FRACP  
 Allan Kroland, M.D.  
 Zvezdan Pirtosek, M.D.  
 Lisa Shulman, M.D.  
 Sharon Stone, M.A.

##### *Creativity and Parkinson's Subcommittee*

Oliver Sacks, M.D. (Honorary  
 Chair)  
 Sharon Stone, M.A. (Chair)  
 David Aigner  
 Mary Baker, MBE  
 Karyn Boyar, R.N.  
 Lucien Cote, M.D.  
 Steven Frucht, M.D.  
 Lizzie Graham  
 Ruth Hagestuen, R.N.  
 Marti Haykin, M.D.  
 Isobel Robins Konecky  
 Arlene Levine  
 Ann Loeb  
 Marshall Loeb  
 Sheree Loftus, M.S.  
 Melanie Marr  
 Laura Marsh, M.D.  
 Michael Pourfar, M.D.  
 Elizabeth Schaaf, MBA  
 Michele Torrecilla  
 Bonnie Wang  
 Jane Baum Waschler  
 Peggy Willocks

#### **Industry Advisory Committee**

Chris Fibiger, Ph.D.  
 Eric Siemers, M.D.  
 Stephen Grate, D.M.V.